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Background: A randomised clinical trial was carried out to study the cost-effectiveness of continuous 
venovenous hemofiltration using high volume and standard volume.  
Methods: Study was done through interviews involving patients or their relatives and document review on 
patients’ treatment and progress note during the hemofiltration therapy in the Intensive Care Unit, Hospital 
University Kebangsaan Malaysia. Study also involved secondary data analysis and a structured questionnaire 
survey to assess the treatment and medical cost incurred by the hospital during the continuous venovenous 
hemofiltration therapy.  
Results: The result of this study showed that the continuous venovenous hemofiltration given at high 
volume 4-6 litres/hour is more cost effective than standard volume of 2 litres/hour. The Sequential Organ Failure 
Assessment (SOFA) score reduction in the high volume hemofiltration is 3.0 units over 24 hours. This reduction is 
higher than the standard volume hemofiltration which is only 0.5 unit over 24 hours.  
Conclusions: High volume hemofiltration is more cost effective than standard volume therapy, where only 
RM 5,552 compared to RM 23,512 is needed for every one unit of SOFA score reduction respectively.  
 





Severe sepsis occurs in 25 percent of patients 
admitted to intensive care units.  It is associated with 
a high mortality rate, ranging from 30 percent to 50 
percent.1  Severe sepsis remains both an important 
clinical challenge and an economic burden in 
intensive care.  Sepsis patients are generally treated 
in intensive care units where close supervision and 
intensive care treatment with adequate equipment can 
be provided.  Sepsis is a major cause of death in 
intensive care units worldwide, with mortality rates 
that range from 20% for sepsis to 40% for severe 
sepsis to more than 60% for septic shock.  In the 
United States, sepsis is the leading cause of death in 
non-coronary ICU patients, and the tenth most 
common cause of death overall according to 2000 
data from the Centers for Disease Control and 
Prevention.2   
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The direct cost of caring for patients with sepsis has 
been shown by Lee et al. in 2004 to be six times 
higher than caring for patients without sepsis.3  The 
manifestations of sepsis include those related to the   
systemic   response   to   infection   (tachycardia, 
tachypnea, alterations in temperature, and 
leukocytosis) and those related to organ-system 
dysfunction (cardiovascular, respiratory, renal, 
hepatic, and hematologic abnormalities).4  Cytokines 
have been implicated as being important endogenous 
mediators in the pathogenesis of sepsis and shock.  
Studies by Taniguchi et al. demonstrated that serum 
tumour necrosis (TNF), interleukin-6 (IL6), and 
interleukin-8 (IL8), are the three of the most 
prominent cytokines, increase during sepsis and are 
associated with an increased occurrence of shock and 
death.5  
 
Continuous Venovenous Hemofiltration Therapy 
 
Continuous Renal Replacement Therapy (CRRT) was 
first described by Peter Kramer in 1977.  CRRT 
offers extraordinary advantages over intermittent 
hemodialysis dan peritoneal dialysis.6 With CRRT, 
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volume control is continuous and immediately 
adaptable to the changing clinical circumstances that 
are common in the care of critically ill patients.  
CRRT is easily tolerated and becomes a useful tool 
for control of intravascular and extravascular volume.  
Patients with acute renal failure and septic shock are 
particularly suited to CRRT.  In these patients 
hemodynamic instability is very common, and 
oliguric and anuric are typical.  If appropriate fluid 
resuscitation, nutrition, blood and blood products 
administration is to take place under optimal 
physiologic circumstances, CRRT must be used. 
 Hemofiltration improves cardiopulmonary 
function and survival by removal of inflammatory 
mediators from the circulation through filtration or 
adsorption.  In continuous venovenous 
hemofiltration, vascular access is achieved by the 
insertion of a double-lumen catheter into a great vein.  
The blood pump is typically  set to deliver 
approximately two litres/hour (standard dose).  A 
servomechanism drives the replacement fluid pump 
at a rate computed either to balance the inflow and 
loss of fluid of to maintain a predetermined rate of 
fluid.  High volume hemofiltration (four litres/hour) 
for short periods (four to six hours) appeared to 
improve hemodynamic and metabolic acidosis status 
promptly.7,8 
 
Cost of sepsis and hemofiltration 
 
The direct cost of treating patients with sepsis has 
been shown to be six times higher than treating 
patients without sepsis.  Cost analysis study by 
Angus et al. in 2001 done in seven selected hospitals 
revealed the average length of hospital stay were 19.6 
days and cost per case were USD 22,000.00 (RM 
83,600.00).1  European studies, Burchardi and 
Schneider, have given estimates direct costs per 
sepsis were ranging from 23,000 Euro to 29,000 Euro 
(RM 110,400.00 to RM 139,200.00).9   The total cost 
of treating sepsis in intensive care unit (ICU) is 
mainly dependent in the length of ICU stay, staffing 
cost, pharmaceuticals and consumables costs.  
Staffing costs represent from 40 percent to 60 percent 
of the total ICU budget.  According to Weber et. al, 
ICU drug costs accounted for 38.4 percent of the total 
budget.10   To date the cost effectiveness of 
hemofiltration therapy in the treatment of sepsis has 
not been established in Malaysia.  There is limited 
information on the hospital costs and resource use 
associated with the care of septic patients.  An 
essential element of this research is therefore to 




Cost-effectiveness analysis is one of the technique of 
economic evaluation designed to compare the costs 
and benefits of a healthcare intervention to assess 
whether it is worth doing.  In  cost-effectiveness 
analysis, the benefits are expressed in non-monetary 
terms related to health effects.  The aim of cost-
effectiveness is to maximize the level of benefits, 
health effects relative to the resources available.11 
Budget constraints increasingly determine the 




The primary objective of this study is to compare the 
cost-effectiveness of two methods of continuous 
venovenous hemofiltration for septiceamic patients in 
the intensive care unit, Hospital Universiti 
Kebangsaan Malaysia.  The two method of treatment 
are the high volume (four to six litres/hour) 
hemofiltration and the standard volume (two 




The specific objectives of this study are: 
a) to carry out cost analysis and to compare 
between the two methods of treatments 
b) to measure the interleukin-6 level before and 
after intervention 
c) to measure the Sequential Organ Failure Assess-
ment (SOFA) before and after intervention 
d) to perform cost-effectiveness analysis and 




It is hypothesized that continuous venovenous 
hemofiltration therapy at high volume for treatment 
of sepsis is more cost effective compared to standard 




Patient  enrollment 
 
This is a clinical trial that evaluated the therapeutic 
effect of continuous venovenous hemofiltration 
therapy for treating sepsis at the intensive care unit, 
Hospital Universiti Kebangsaan Malaysia.  This 
study was conducted in 33 adults aged 21 years to 79 
years who presented to the hospital with infection, 
systemic inflammatory response syndrome, 
dysfunctional organs or systems and septic shock.  
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Any patient with end-stage renal disease, underlying 
malignancy, acquired immuno-deficiency syndrome 
and a life expectancy less than six months were 
excluded from the trial.   
Intervention  
 
The treatment was randomized at an individual level 
using block randomization comprising of three 
groups of ten patients of equal allocation of patients 
towards High-Volume Hemofiltration (HVHF) and 
Continuous Veno-Venous Hemofiltration (CVVH, 
standard dose).   The patients were blinded to the 
subject’s treatment status.  Patients were randomly 
assigned to six hours of high volume hemofiltration 
in addition to the usual care (n=15), or to standard 
dose of continuous venovenous hemofiltration in 
addition to the usual care (n=18).  The treatment 
started within four hours of fulfillment of 
randomization criteria.  Patients were subjected to the 
standard intensive care unit treatment protocol and 
the usual resuscitative measures were optimized.   
 
Measurements of clinical outcomes 
 
The patients were assessed every 24 hours till 
discharge using the Sequential Organ Failure 
Assessment (SOFA) score.  The SOFA score is 
composed of scores from six organ systems 
(respiratory, cardiovascular, hepatic, coagulation, 
renal, and neurological) graded from 0 to 4 according 
to the degree of dysfunction/failure. The aggregate 
score (total maximum SOFA score) is calculated 
summing the worst scores for each of the organ 
systems during the ICU stay. The SOFA scores were 
calculated at the time of recruitment and daily 
thereafter until death or discharge from the intensive 
care unit, or at 28 days whichever is earlier.  Any 
complications such as bleeding, hematoma, arterial 
puncture and vascular thrombosis were recorded.  
Patients were closely monitored for any deteriorating 
conditions.  The concentration levels of inflammatory 
mediator, the interleukin-6 were measured before 
intervention, at three hour, six hour and 24 hour of 
patient’s hospital stay. 
 
Identifying and Measuring Costs 
 
The cost data was collected to identify the cost 
incurred for the management of sepsis with 
hemofiltration therapy from the provider’s 
perspective.  The resources utilized for the 
management of sepsis with hemofiltration therapy 
and their unit costs were measured in order to 
determine the cost of treatment.  We enumerated 
every input consumed by the patient and then its unit 
cost.  This is known as micro-costing.  The 
measurement of the resources utilized was from the 
time of recruitment and during the study period.  The  
medical cost to the hospital was the expenditure 
incurred by the hospital administration after 
randomization.  The medical costs were divided into 
two categories, the capital and recurrent costs.  
 The capital costs included the building and 
equipment costs.  The recurrent costs included 
operational costs, the services provided by the 
medical personnel, the medications, the laboratory 
investigations, the imaging investigations, and the 
consumables.  We estimated the building costs based 
on 20 years lifespan at five percent discount rate 
times the proportion of the intensive care unit surface 
area.  We estimated the equipment costs based in five 
years lifespan at five percent discount rate.  The 
operational cost includes the utility costs, engineering 
and maintenance costs, cleaning, gardening, clinical 
waste disposable management, laundry and costs of 
food.  We estimated the operational cost based on 
average length of stay and unit surface area of the 
intensive care unit.  The costs of service provided by 
the medical personnel, was calculated based on their 
salary times the proportion of their time spent 
rendering to the treatment.  The costs of drugs and 
consumables were the manufacture’s wholesale price.  
We estimated the laboratory and the imaging 
investigation costs using the hospital’s inpatient 
charges.  The cost of treatment for a patient, at the 
intensive care unit, Hospital Universiti Kebangsaan 
Malaysia, was calculated by summing the average 
costs calculated per day multiply by the total length 
of stay. 
 
Statistical and Economic Analysis 
 
The costs of the treatment for each patient was 
calculated by dividing the total costs with the number 
of respondents.  The median of the total medical 
costs which included the capital and the recurrent 
costs were estimated.  We also calculated the median 
of the capital and the recurrent costs in both HVHF 
and CVVH groups.   
 For the purpose of calculating the cost-
effectiveness ratio for each group, we used total 
medical costs as the numerator and the difference in 
the SOFA score as the denominator (difference of 
SOFA score between the time of recruitment and at 
24 hours after intervention).  
 The Statistical Package for the Social 
Science (SPSS) version 11.0 was used for the 
statistical analyses.  The difference of socio-
demographic and economic status, capital costs, 
recurrent costs, SOFA score and plasma 
concentration level of interleukin-6 between the high 
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volume and the standard dose were analyzed using 
the non-parametric test, Mann-Whitney U test.  A 
p<0.05 was considered significant.  Results are 





A total of 33 patients were selected in the study and 
were randomized to hemofiltration at high volume 
(n=15) and hemofiltration at standard dose (n=18) 
groups.  The socio-demographic and economic status 
of the patients in the two groups were similar as 
shown in Table 1.  The health outcomes in the high 
volume hemofiltration group were favorable but 
failed to reach significant level.  The high volume 
hemofiltration group showed clinically more 
reductions in concentration level of interleukin-6.  
The SOFA scores found to be decreased after 24 
hours intervention in both groups.  However, the 
reduction was more in the high volume 
hemofiltration compared to the standard dose 
hemofiltration (Table 2). 
 
                            Table 1:  The socio-demographic and economic status of respondents 
 
 Number of patient (%)  







    
Gender                Male 8 (42.1) 11 (57.9) 0.653 
                             Female 7 (50.0) 7 (50.0)  
    
Age                       0-30 years 1 (33.3) 2 (66.7) 0.867 
                              31-60 years 8 (44.4) 10 (55.6)  
                              61-90 years 6 (50.0) 6 (50.0)  
    
Ethnic                   Malay 10 (50.0) 10 (50.0) 0.793 
                              Chinese 4 (40.0) 6 (60.0)  
                              Indian 1 (33.3) 2 (66.7)  
    
Monthly income   0-RM 500 10 (47.6) 11 (52.4) 0.491 
                               RM 501-RM 1000 3 (37.5) 5 (62.5)  
                               RM 1001-RM 1500 2 (50.0) 2 (50.0)  
    
 
 




High volume hemofiltration Standard dose hemofiltration p value 
     
 Interleukin-6    
 Before intervention 119.5 (24.7-317.8) 159.9 (21.4-303.2) 0.745 
 At 3 hour 119.2 (14.1-312.4) 131.1 (19.3-313.2) 0.613 
 At 6 hour 61.3 (11.0-304.2) 162.3 (0-301.8) 0.406 
 At 24 hour 63.8 (10.3-319.0) 190.2 (27.7-311.5) 0.423 
     
 SOFA score    
 Before intervention 13.0 (5-20) 9.5 (6-22) 0.336 
 At 24 hour 10.0 (3-21) 9.0 (4-21) 0.691 
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Cost and Effectiveness Outcomes 
The average total cost of treating a sepsis patient with 
high volume hemofiltration was RM 16,657.  The 
average total cost of treating a sepsis patient with 
standard dose hemofiltration was RM 11,756 (Table 
3).    The hospital spent a total of RM 249,849.00 for 
15 septic patients selected for the hemofiltration at 
high volume.  The hospital had to spend a total of 
RM 211,612.00 for 18 septic patients selected for the 
hemofiltration at standard dose (Table 3).   However, 
the median cost of treating septic patients incurred by 
the hospital in the high volume and the standard dose 
hemofiltration, were not significantly different.  The 
median capital costs and recurrent costs were similar 
in both groups (Table 4). 
 The cost-effectiveness of the treatment is 
shown in Table 5.  Results showed that  RM 5,552 is 
required for every one unit reduction of SOFA score 
for high volume hemofiltratration.  On the other 
hand, about RM 23,512 had to spend for every one 
unit reduction of SOFA score in the standard dose 
hemofiltration.  The high volume is more cost-




Table 3:  Cost analysis on treatment of septic patient with high volume and standard dose hemofiltration 
in  the intensive care unit based on year 2004 expenditure (in Ringgit Malaysia). 
 
 





Capital cost Building 264 198 
 Equipment 27,484 20,613 
Recurrent cost Operational 538 403 
  Staff 93,304 69,978 
  Pharmaceutical 74,781 61,728 
  Laboratory 23,293 22,554 
  Imaging 2755 4515 
  Consumables 27,430 31,623 
Total cost   249,849 211,612 
Total number of patient  15 18 
Average length of stay  16 11.3 






Table 4:  Cost analysis of hemofiltration treatments  
 
High volume hemofiltration Standard dose  
hemofiltration 
p value Category 
 
Median Range Median Range  
Capital cost      
    Building 11.85 3.09-39.14 9.27 3.90-33.99 0.125 
    Equipment 1234.64 322.08-4079.68 966.24 322.08-3542.88 0.125 
Recurrent cost      
    Operational 24.15 6.30-79.80 18.90 6.30-69.30 0.125 
    Staff 4191.40 1093.41-13849.86 3280.23 1093.41-12027.51 0.125 
    Pharmaceutical 3281.86 1221.32-13816.43 3291.47 419.71-12310.13 0.368 
    Consumables 3019.21 1920.30-6472.79 2963.89 2079.24-5974.16 0.387 
    Imaging 95.00 45.00-430.00 170.00 40.00-830.00 0.651 
    Laboratory 1387.50 710.00-4007.00 1319.00 500.00-3603.00 0.387 
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Table 5:  Cost-effectiveness of hemofiltration treatment  








   
Before intervention 13.0 9.5 
After 24 hours intervention 10.0 9.0 
Difference in SOFA score 3.0 0.5 
Total cost RM 16,657 RM 11,756 
Cost-effectiveness 










Continuous venovenous hemofiltration is well 
established and a cost-effective strategy for reducing 
sepsis mortality.  It is also widely accepted.  
Continuous venovenous hemofiltation is increasingly 
used to treat acute renal failure in critically ill 
patients, but a clear definition of an adequate 
treatment dose has not been established.  Delivering 
hemofiltration at higher volume in the treatment of 
septicemia could be of benefit in reducing septicemia 
mortality and morbidity.  Any changes recommended 
in the rate of hemofiltration from its standard dose 
(two litres/hour), needs reasonable justification in 
terms of efficacy and costs.  Our study showed that 
high volume hemofiltration four to six litres/hour had 
beneficial effects on the reduction of SOFA score.  
This gives an important costs implication. 
 In Malaysia, there is little information on the 
costs associated with the treatment of septicemia and 
renal replacement therapy.  In this study, the average 
cost of treating septicemia with standard dose 
hemofiltration was RM 11,756 per episode of in 
patient admitted to the intensive care unit, Hospital 
Universiti Kebangsaan Malaysia.  The average cost 
of treating septicemia with high volume 
hemofiltration was RM 16,657 per episode.  The total 
cost of the high volume hemofiltration were 40 
percent more than the total cost of the standard dose.  
The differences are noted on the aspects of staff and 
equipment. However these differences are not 
statistically significant. The cost-effectiveness ratio 
was calculated as the total costs divided by the 
difference in health outcomes.  The unit of health 
interest and the effectiveness measure for this study 
was the reduction of SOFA score before and after 24 
hours intervention.  We believe that it is a pragmatic 
and good proxy measure for septicemia morbidity 
and mortality for assessing cost-effectiveness.  
  
 
This study showed that, high volume 
hemofiltration (4-6 litres/hour) was more cost-
effective compared to the standard dose 
hemofiltration.  A total of RM 5,552 had to be spent 
for every one unit of SOFA score reduction in high 
volume hemofiltration.  Comparatively, estimated 
about RM 23,512 had to be spent for every one unit 
of SOFA score reduction for the standard dose 
hemofiltration.   
A sensitivity analysis were performed, 
where the discount rates on capital costs was changed 
to one percent and ten percents, and the hospital stay 
was changed to minimum and maximum duration.  
Sensitivity analysis of the results helps to determine 
its robustness and its performance in a dynamic 
environment, where variations in costs and benefits 
occur due to variation in measurements and 
implementation of the intervention.  The sensitivity 
analysis results remained the same where the high 
volume hemofiltration is more cost-effective 
compared to the standard dose hemofiltration. 
 The average costs of septicemia treatment in 
the intensive care unit, Hospital Universiti 
Kebangsaan Malaysia, was 5.9 times cheaper, and 1.5 
times less in average length of stay compared to the 
cost of septicemia treatment in United States of 
America.  The cost of treatment in developing 
countries is considerably less because of diverse 
health care systems, different hospital capacity, their 
scope and their sources of funding, price differences 
in the pharmaceuticals and consumables.  The main 
contribution of total costs for treating septicemia with 
continuous venovenous hemofiltration in our study 
were staffing (40 percent), pharmaceutical (33 
percent), consumables (14 percent) and laboratory 
(11 percent) respectively.  The severity of illness and 
the length of hospital stay were the most important 
contributors of total cost.   As expected, the use of 
intravenous fluids and antibiotics inflated the costs of 
treatment.  The costs of original drugs were more 
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expensive compared to the generic drugs.  According 
to Carnahan, cost of generic drugs in United States of 
America is 74 percent more cheaper than the original 
brand.12  The cost of generic drugs in Canada is 38 
percent cheaper than the original drugs.  
 Septicemia is a clinically defined entity of 
altered and malfunction of multiple organs function 
resulting from a systemic response to infection.  The 
management of patient with severe sepsis includes 
combination of various drugs such as antibiotics, 
inotropic agents, parenteral nutrition, and others. Cost 
analysis study by PrincewaterhouseCoopers, found 
that hospital incurred 38.8 percent for staffing costs, 
and 24 percent for pharmaceuticals costs from the 
overall inpatient expenditure.13   
The cost of consumables (hemofilter, blood 
and fluid lines, double lumen catheter, replacement 
fluid, empty bag, manifold three way spike, and 
normal saline), for each episode of high volume 
hemofiltration therapy in our unit was RM 1,461 and 
for each episode of standard dose hemofiltration 
therapy was RM  1,640.  This findings was definitely 
cheaper that the costs of hemofiltration done by Forni 
and Hilton.14   They found that for treatment lasting 
an average of 9.3 days, with replacement of 
extracorporeal circuit every 2.5 days, the cost of 
consumables for each episode of acute renal failure 




An emphasis on the costs and economic benefits of 
an alternative therapy is an important aspect of health 
services research.  This study showed that cost-
effectiveness analysis is a good and accurate form of 
economic evaluation in which the costs of 
alternatives treatments are compared.  We found that 
severe sepsis consumes considerable health care 
resources, and is associated with a high mortality 
rate.  This study found that despite the total cost per 
episode is higher in the high volume hemofiltration, it 
is more cost-effective compared to standard dose.  
The cost savings and the attractive cost-effectiveness 
indicates the need to further assess the role of high 
volume hemofiltration therapy in the treatment of 
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